サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1463834

中東・アフリカの呼吸器管感染症治療：市場規模および予測、地域シェア、動向、成長機会分析レポート、薬剤別、適応疾患別、投与経路別、年齢層別、流通チャネル別、国別

MEA Respiratory Tract Infection Treatment Market Size and Forecast, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country

出版日
ページ情報
英文 201 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
中東・アフリカの呼吸器管感染症治療：市場規模および予測、地域シェア、動向、成長機会分析レポート、薬剤別、適応疾患別、投与経路別、年齢層別、流通チャネル別、国別
出版日: 2024年03月18日
発行: The Insight Partners
ページ情報: 英文 201 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

中東・アフリカの呼吸器管感染症治療市場規模は2023年の20億9,000万米ドルから2031年には29億7,000万米ドルに成長すると予測され、2023年から2031年までのCAGRは4.50%と推定されます。

呼吸器管感染症治療のためのOTC製品に対する需要の急増が中東・アフリカの呼吸器管感染症治療市場の成長機会

膨大な数の消費者が、咳、鼻づまり、喉の痛みなどの一般的な呼吸器症状に対して、アクセスしやすく便利な解決策を求めています。このアプローチは、生命を脅かす病気に罹患していない個人にも、自分の健康を注意深く監視し管理する力を与えます。また、メーカー、薬局、ヘルスケアプロバイダーは、提供する製品をより一般用医薬品（OTC）に適したものにし、セルフケアの実践について消費者を教育し、さまざまな症状の緩和をもたらす治療オプションへのアクセスを改善することができます。OTC呼吸器治療薬の人気が急上昇していることは、呼吸器の健康に対する認識を促進し、自己管理戦略と協力的なヘルスケア・エコシステムを育成することの重要性を強調しています。OTC呼吸器治療薬の人気の高まりを活用することで、中東・アフリカの呼吸器管感染症治療市場の利害関係者は、患者との関わりを強化し、予防医療対策を促進し、多様な人々の進化するヘルスケアニーズに対応することができます。このように、呼吸器感染症を管理するためのOTC製品に対する需要の増加は、中東・アフリカの呼吸器管感染症治療市場にとって大きなビジネスチャンスとなっています。

薬剤ベースの洞察

薬剤別では、抗生物質分野が2023年の中東・アフリカの呼吸器管感染症治療市場で最大のシェアを占めました。2023～2031年のCAGRは抗生物質が最も高いと予測されます。呼吸器感染症には、気管支炎、肺炎、副鼻腔炎などさまざまな疾患が含まれ、細菌性病原体によって引き起こされることが多いです。

疾患適応症に基づく洞察

疾患適応症に基づくと、2023年には下気道感染症分野がより大きな市場シェアを占めています。さらに、2023年から2031年にかけてより高いCAGRを記録すると予測されています。下気道感染症（LRTI）は、肺や気管支に影響を及ぼす感染症であり、通常、細菌性、ウイルス性、真菌性病原体などによって引き起こされます。

投与経路別の洞察

投与経路別では、経口剤が中東・アフリカの呼吸器管感染症治療市場で大きなシェアを占めており、同分野は2023～2031年に高いCAGRを記録すると予測されています。アモキシシリン、アジスロマイシン、ドキシサイクリンなどの経口抗生物質は、呼吸器感染症を引き起こす細菌病原体と闘うために頻繁に処方されます。

年齢層別の洞察

年齢層別では、2023年の中東・アフリカの呼吸器管感染症治療市場では成人セグメントが大きなシェアを占めています。小児科セグメントは2023～2031年の間、より高いCAGRを記録すると予測されています。小児の呼吸器感染症有病率の高さは、効果的な治療オプションの必要性を促進する主要因です。

流通チャネル別の洞察

流通チャネル別では、2023-2031年に病院薬局セグメントが大きな市場シェアを占めると予測されます。病院薬局は医療システムの重要な構成要素として機能しており、特に、静脈内または筋肉内投与が必要な急性および重症の呼吸器感染症の管理において重要な役割を果たしています。

中東・アフリカの呼吸器管感染症治療市場に関する報告書作成にあたり参照した主な一次情報および二次情報は、ドバイ保健当局、サウジアラビア喘息イニシアチブ、サウジアラビア胸部学会などです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 中東・アフリカの呼吸器管感染症治療市場情勢

  • PEST分析

第5章 中東・アフリカの呼吸器管感染症治療市場：主要市場力学

  • 中東・アフリカの呼吸器管感染症治療市場- 主要市場力学
  • 主な市場促進要因
    • 中東における呼吸器感染症患者の増加
    • 呼吸器系感染症に関する意識の高まり
  • 主な市場抑制要因
    • 呼吸器治療薬に焦点を当てた調査の不足
  • 主な市場機会
    • 呼吸器管感染症治療のためのOTC製品に対する需要の急増
  • 今後の動向
    • MERSに対する抗ウイルス治療の登場
  • 促進要因と抑制要因の影響

第6章 中東・アフリカの呼吸器管感染症治療市場分析

  • 中東・アフリカの呼吸器管感染症治療市場の収益、2023-2031年

第7章 中東・アフリカの呼吸器管感染症治療市場分析：医薬品別

  • 抗生物質
  • 非ステロイド性抗炎症薬
  • 咳止め薬
  • 鼻腔充血除去薬

第8章 中東・アフリカの呼吸器管感染症治療市場分析：適応疾患別

  • 下気道感染症
  • 上気道感染症

第9章 中東・アフリカの呼吸器管感染症治療市場分析：投与経路別

  • 経口
  • 非経口

第10章 中東・アフリカの呼吸器管感染症治療市場分析：年齢層別

  • 小児
  • 成人

第11章 中東・アフリカの呼吸器管感染症治療市場分析：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第12章 中東・アフリカの呼吸器管感染症治療市場：国別分析

  • 中東およびアフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • 中東・アフリカのその他

第13章 企業プロファイル

  • Abbott Laboratories
  • Teva Pharmaceutical Industries Ltd
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • AstraZeneca Plc
  • Alembic Pharmaceuticals Ltd
  • GSK Plc
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Gulf Pharmaceutical Industries Co

第14章 付録

図表

List Of Tables

  • Table 1. MEA Respiratory Tract Infection Treatment Market Segmentation
  • Table 2. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Drugs
  • Table 3. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Disease Indication
  • Table 4. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Route Of Administration
  • Table 5. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Age Group
  • Table 6. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 7. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Country
  • Table 8. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Drugs
  • Table 9. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Disease Indication
  • Table 10. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Route Of Administration
  • Table 11. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Age Group
  • Table 12. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 13. South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Drugs
  • Table 14. South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Disease Indication
  • Table 15. South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Route Of Administration
  • Table 16. South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Age Group
  • Table 17. South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 18. UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Drugs
  • Table 19. UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Disease Indication
  • Table 20. UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Route Of Administration
  • Table 21. UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Age Group
  • Table 22. UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 23. REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Drugs
  • Table 24. REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Disease Indication
  • Table 25. REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Route Of Administration
  • Table 26. REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Age Group
  • Table 27. REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 28. Glossary of Terms, MEA Respiratory Tract Infection Treatment Market

List Of Figures

  • Figure 1. MEA Respiratory Tract Infection Treatment Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. MEA Respiratory Tract Infection Treatment Market Revenue (US$ Million), 2023-2031
  • Figure 5. MEA Respiratory Tract Infection Treatment Market Share (%) - by Drugs, 2023 and 2031
  • Figure 6. Antibiotics: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. NSAIDs: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Cough Suppressants: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Nasal Decongestants: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. MEA Respiratory Tract Infection Treatment Market Share (%) - by Disease Indication, 2023 and 2031
  • Figure 11. Lower Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Upper Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. MEA Respiratory Tract Infection Treatment Market Share (%) - by Route Of Administration, 2023 and 2031
  • Figure 14. Oral: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Parenteral: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. MEA Respiratory Tract Infection Treatment Market Share (%) - by Age Group, 2023 and 2031
  • Figure 17. Pediatrics: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Adults: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. MEA Respiratory Tract Infection Treatment Market Share (%) - by Distribution Channel, 2023 and 2031
  • Figure 20. Hospital Pharmacies: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Retail Pharmacies: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Online Pharmacies: MEA Respiratory Tract Infection Treatment Market- Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. MEA Respiratory Tract Infection Treatment Market Breakdown by Key Countries, 2023 and 2031 (%)
  • Figure 24. MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 25. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
目次
Product Code: TIPRE00038996

The MEA respiratory tract infection treatment market size is expected to grow from US$ 2.09 billion in 2023 to US$ 2.97 billion by 2031; it is estimated to register a CAGR of 4.50% from 2023 to 2031.

Surge in Demand for OTC Products to Treat Respiratory Infections Opportunity for Growth of MEA Respiratory Tract Infection Treatment Market

A vast number of consumers seek accessible and convenient solutions for common respiratory symptoms such as cough, congestion, and sore throat. This approach empowers individuals who are not suffering from life-threatening diseases to closely monitor and control their health. It also allows manufacturers, pharmacies, and healthcare providers to make their product offerings more suitable for over-the-counter (OTC) applications, educate consumers on self-care practices, and improve access to treatment options providing relief from various symptoms. The burgeoning popularity of OTC respiratory remedies underlines the importance of promoting respiratory health awareness, fostering self-management strategies and a collaborative healthcare ecosystem. By leveraging the rising popularity of OTC respiratory products, the respiratory tract infection treatment market stakeholders in the MEA can enhance patient engagement, promote preventive healthcare measures, and address the evolving healthcare needs of diverse populations. Thus, the increasing demand for OTC products to manage respiratory infections represents a significant opportunity for the MEA respiratory tract infection treatment market.

Drug -Based Insights

In terms of drug, the antibiotics segment held the largest MEA respiratory tract infection treatment market share in 2023. The same is anticipated to register the highest CAGR during 2023-2031. Respiratory tract infections encompass a range of ailments, including bronchitis, pneumonia, and sinusitis, often caused by bacterial pathogens.

Disease Indication -Based Insights

Based on disease indication, the lower respiratory tract infection segment held a larger market share in 2023. It is further anticipated to register a higher CAGR from 2023 to 2031. Lower respiratory tract infections (LRTIs) are infections that affect the lungs and bronchial tubes, typically caused by bacterial, viral, or fungal pathogens, among others.

Route Of Administration -Based Insights

By route of administration, the oral segment held a larger share of the MEA respiratory tract infection treatment market; the same segment is anticipated to register a higher CAGR during 2023-2031. Oral antibiotics such as amoxicillin, azithromycin, or doxycycline are frequently prescribed to combat bacterial pathogens causing respiratory tract infections.

Age Group -Based Insights

In terms of age group, the adult segment held a larger share of the MEA respiratory tract infection treatment market in 2023. The pediatrics segment is anticipated to register a higher CAGR during 2023-2031. The high prevalence of respiratory tract infections among children is a key factor driving the need for effective treatment options.

Distribution Channel -Based Insights

In terms of distribution channel, the hospital pharmacies segment is anticipated to account for a significant market share during 2023-2031. Hospital pharmacies serve as key components of a healthcare system; they particularly play a vital role in the management of acute and severe respiratory tract infections, which require intravenous or intramuscular administration of medications.

A few of the major primary and secondary sources referred to while preparing the report on the MEA respiratory tract infection treatment market are the Dubai Health Authority, Saudi Initiative for Asthma, Saudi Thoracic Society.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. MEA Respiratory Tract Infection Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. MEA Respiratory Tract Infection Treatment Market - Key Market Dynamics

  • 5.1 MEA Respiratory Tract Infection Treatment Market - Key Market Dynamics
  • 5.2 Key Market Drivers
    • 5.2.1 Rising Cases of Respiratory Infections in Middle East
    • 5.2.2 Increasing Awareness Related to Respiratory Tract Infections
  • 5.3 Key Market Restraints
    • 5.3.1 Lack of Research Focused on Respiratory Therapeutics
  • 5.4 Key Market Opportunities
    • 5.4.1 Surge in Demand for OTC Products to Treat Respiratory Infections
  • 5.5 Future Trends
    • 5.5.1 Advent of Antiviral Treatment for MERS
  • 5.6 Impact of Drivers and Restraints:

6. MEA Respiratory Tract Infection Treatment Market Analysis

  • 6.1 MEA Respiratory Tract Infection Treatment Market Revenue (US$ Million), 2023-2031

7. MEA Respiratory Tract Infection Treatment Market Analysis - by Drugs

  • 7.1 Antibiotics
    • 7.1.1 Overview
    • 7.1.2 Antibiotics: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 NSAIDs
    • 7.2.1 Overview
    • 7.2.2 NSAIDs: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Cough Suppressants
    • 7.3.1 Overview
    • 7.3.2 Cough Suppressants: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Nasal Decongestants
    • 7.4.1 Overview
    • 7.4.2 Nasal Decongestants: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

8. MEA Respiratory Tract Infection Treatment Market Analysis - by Disease Indication

  • 8.1 Lower Respiratory Tract Infection
    • 8.1.1 Overview
    • 8.1.2 Lower Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Upper Respiratory Tract Infection
    • 8.2.1 Overview
    • 8.2.2 Upper Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

9. MEA Respiratory Tract Infection Treatment Market Analysis - by Route Of Administration

  • 9.1 Oral
    • 9.1.1 Overview
    • 9.1.2 Oral: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Parenteral
    • 9.2.1 Overview
    • 9.2.2 Parenteral: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

10. MEA Respiratory Tract Infection Treatment Market Analysis - by Age Group

  • 10.1 Pediatrics
    • 10.1.1 Overview
    • 10.1.2 Pediatrics: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Adults
    • 10.2.1 Overview
    • 10.2.2 Adults: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

11. MEA Respiratory Tract Infection Treatment Market Analysis - by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Overview
    • 11.1.2 Hospital Pharmacies: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.2 Retail Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Retail Pharmacies: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.3 Online Pharmacies
    • 11.3.1 Overview
    • 11.3.2 Online Pharmacies: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)

12. MEA Respiratory Tract Infection Treatment Market - Country Analysis

  • 12.1 Middle East and Africa
    • 12.1.1 MEA Respiratory Tract Infection Treatment Market Breakdown by Countries
    • 12.1.2 MEA Respiratory Tract Infection Treatment Market Revenue and Forecast and Analysis - by Country
    • 12.1.3 MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2030
      • 12.1.3.1 MEA Respiratory Tract Infection Treatment Market Revenue and Forecast and Analysis - by Country
      • 12.1.3.2 Saudi Arabia
      • 12.1.3.3 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.3.3.1 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs
        • 12.1.3.3.2 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication
        • 12.1.3.3.3 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration
        • 12.1.3.3.4 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group
        • 12.1.3.3.5 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel
      • 12.1.3.4 South Africa
      • 12.1.3.5 South Africa: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.3.5.1 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs
        • 12.1.3.5.2 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication
        • 12.1.3.5.3 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration
        • 12.1.3.5.4 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group
        • 12.1.3.5.5 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel
      • 12.1.3.6 UAE
      • 12.1.3.7 UAE: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.3.7.1 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs
        • 12.1.3.7.2 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication
        • 12.1.3.7.3 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration
        • 12.1.3.7.4 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group
        • 12.1.3.7.5 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel
      • 12.1.3.8 Rest of MEA
      • 12.1.3.9 REST of MEA: MEA Respiratory Tract Infection Treatment Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.3.9.1 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs
        • 12.1.3.9.2 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication
        • 12.1.3.9.3 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration
        • 12.1.3.9.4 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group
        • 12.1.3.9.5 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel

13. Company Profiles

  • 13.1 Abbott Laboratories
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Teva Pharmaceutical Industries Ltd
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Sanofi SA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Boehringer Ingelheim International GmbH
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 AstraZeneca Plc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Alembic Pharmaceuticals Ltd
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 GSK Plc
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Novartis AG
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 F. Hoffmann-La Roche Ltd
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Gulf Pharmaceutical Industries Co
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms